Augmedix, a US-based developer of healthcare technology using the Google Glass headset, yesterday added $23m to its coffers thanks to investors including pharmaceutical firm McKesson.
The corporate, which participated through its investment arm McKesson Ventures, joined OrbiMed, Redmile Group, Emergence Capital and DCM Ventures.
Founded in 2012, Augmedix’s technology relies on augmented reality headset Google Glass to record and chart a patients symptoms, prescriptions and lab tests without the need for physicians to manually enter the data into medical records.
The company will put the money towards further expansion in the US and the development of additional features for its platform.
Augmedix has now raised more than $60m. Healthcare systems Sutter Health, Dignity Health, Catholic Health Initiatives, TriHealth and an undisclosed fifth peer previously supplied fund to a $17m funding round in April 2016 led by Redmile with support from Emergence and DCM.
Emergence and DCM also invested $7m in a seed round before returning for a $16m series A round in January 2015.
Tom Rodgers, senior vice-president and managing director of McKesson Ventures, said: “Augmedix is uniquely able to improve doctors’ quality of life by allowing them to concentrate on their patients rather than on data entry.
“This makes their technology invaluable for settings like our US oncology clinics. We are excited to bring McKesson’s experience and ubiquitous market presence to help them scale to doctors across the country in the coming few years.”